Filtered By:
Cancer: Breast Cancer
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 63039 results found since Jan 2013.
Author Correction: Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes
Sci Rep. 2023 Sep 15;13(1):15294. doi: 10.1038/s41598-023-42606-z.NO ABSTRACTPMID:37714994 | PMC:PMC10504286 | DOI:10.1038/s41598-023-42606-z
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Nanna B æk Møller Desir ée Sofie Boonen Elisabeth Simone Feldner Qin Hao Martin Larsen Anne-Vibeke L ænkholm Åke Borg Anders Kvist Therese T örngren Uffe Birk Jensen Susanne Eriksen Boonen Mads Thomassen Thorkild Terkelsen Source Type: research
Low interobserver agreement among subspecialised breast pathologists in evaluating HER2-low breast cancer
CONCLUSIONS: Subspecialised breast pathologists have suboptimal agreement for immunohistochemical evaluation of HLBC using the modified Ki-67 methodology. An urgent need remains for a new assay/algorithm to reliably evaluate HLBC.PMID:37714693 | DOI:10.1136/jcp-2023-209055
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Gulisa Turashvili Yuan Gao Di Andy Ai Abdulwahab M Ewaz Sandra Gjorgova Gjeorgjievski Qun Wang Thi T A Nguyen Chao Zhang Xiaoxian Li Source Type: research
Personalizing Breast Cancer Care
Surg Oncol Clin N Am. 2023 Oct;32(4):xv-xvi. doi: 10.1016/j.soc.2023.06.001. Epub 2023 Jun 21.NO ABSTRACTPMID:37714647 | DOI:10.1016/j.soc.2023.06.001
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Melissa Pilewskie Source Type: research
Lasting Impacts of the COVID-19 Pandemic on Breast Cancer Diagnosis and Treatment in the United States
Surg Oncol Clin N Am. 2023 Oct;32(4):811-819. doi: 10.1016/j.soc.2023.05.010. Epub 2023 May 10.ABSTRACTThe COVID-19 pandemic was an unprecedented time that placed unique challenges on the screening and treatment of breast cancer in the United States. Collaboration among medical disciplines and societies provided guidelines and strategies to mitigate the exposure of patients and medical providers to the virus and provide optimal care. We discuss the changes that the pandemic had on the multidisciplinary management of breast cancer.PMID:37714645 | PMC:PMC10169575 | DOI:10.1016/j.soc.2023.05.010
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Jenna L Sturz Judy C Boughey Source Type: research
Addressing Inequalities in Breast Cancer Care Delivery
Surg Oncol Clin N Am. 2023 Oct;32(4):799-810. doi: 10.1016/j.soc.2023.05.009. Epub 2023 Jun 16.ABSTRACTBreast cancer treatment, timeliness of care, and clinical outcomes are inferior for patients of Black race and Hispanic ethnicity, and the origin of these inequities is multifactorial. Owing to aggregate reporting of data in the United States for patients of Asian, Native Hawaiian, and Pacific Islander ancestry, disparities within and across these groups are difficult to appreciate. In large part due to low prevalence, male breast cancer remains understudied, and treatment algorithms are primarily extrapolated from resear...
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Leisha C Elmore Oluwadamilola M Fayanju Source Type: research
Incorporating Value-Based Decisions in Breast Cancer Treatment Algorithms
Surg Oncol Clin N Am. 2023 Oct;32(4):777-797. doi: 10.1016/j.soc.2023.05.008. Epub 2023 Jun 9.ABSTRACTGiven the excellent prognosis and availability of evidence-based treatment, patients with early-stage breast cancer are at risk of overtreatment. In this review, we summarize key opportunities to incorporate value-based decisions to optimize the delivery of high-value treatment across the breast cancer care continuum.PMID:37714643 | DOI:10.1016/j.soc.2023.05.008
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Ton Wang Lesly A Dossett Source Type: research
Prepectoral Versus Subpectoral Implant-Based Reconstruction: How Do We Choose?
This article aims to review developments in prosthetic breast reconstruction and provide recommendations to help providers choose whether prepectoral or subpectoral reconstruction in the best approach for each of their patients.PMID:37714642 | DOI:10.1016/j.soc.2023.05.007
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Perri S Vingan Minji Kim Danielle Rochlin Robert J Allen Jonas A Nelson Source Type: research
Fertility and Sexual Health in Young Women with Early-Stage Breast Cancer
Surg Oncol Clin N Am. 2023 Oct;32(4):747-759. doi: 10.1016/j.soc.2023.05.012. Epub 2023 Jun 15.ABSTRACTFertility and sexual health may be impaired by early breast cancer treatment in young women, and these issues should be addressed at diagnosis and through survivorship. Future fertility interest and risk should be considered and communicated, and early referral made to an infertility specialist for those interested. Data regarding safety of fertility preservation options as well as pregnancy after breast cancer are overall reassuring. Patients should be counseled about the impact of systemic therapies and breast surgeries...
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Marla Lipsyc-Sharf Ann H Partridge Source Type: research
Selecting Triple Negative Breast Cancer Patients for Immunotherapy
Surg Oncol Clin N Am. 2023 Oct;32(4):733-745. doi: 10.1016/j.soc.2023.05.005. Epub 2023 Jun 5.ABSTRACTThe approval of preoperative immunotherapy combined with chemotherapy is a practice-changing advance for patients with early-stage triple-negative breast cancer. The optimal patient selection requires careful attention to staging and balancing potential risks with expected benefits, particularly as it relates to immune-related adverse events.PMID:37714640 | DOI:10.1016/j.soc.2023.05.005
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Stephanie Downs-Canner Elizabeth A Mittendorf Source Type: research
Incorporating Tumor Biology to Select Patients for the Omission of Radiation Therapy
Surg Oncol Clin N Am. 2023 Oct;32(4):725-732. doi: 10.1016/j.soc.2023.05.006. Epub 2023 Jun 9.ABSTRACTAlthough adjuvant breast radiotherapy has long been a universal component of breast conservation therapy (BCT), it is now clear that "breast cancer" is a broad class of many disparate diseases with varying natural histories and risk profiles. In turn, some breast conservation patients enjoy exceedingly favorable outcomes following surgery alone. Ongoing trials seek to identify such low-risk patient populations, hypothesizing that some may safely forego radiotherapy. Whereas prior-generation trials focused on clinicopatholo...
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Lior Z Braunstein Source Type: research
Managing the Morbidity: Individualizing Risk Assessment, Diagnosis, and Treatment Options for Upper Extremity Lymphedema
Surg Oncol Clin N Am. 2023 Oct;32(4):705-724. doi: 10.1016/j.soc.2023.05.004. Epub 2023 Jun 25.ABSTRACTIn the setting where breast cancer-related lymphedema (BCRL) remains a feared and common complication of breast cancer, here we review important factors for the development, diagnosis, prevention, and treatment of BCRL. We find that race/ethnicity affect BCRL development risk, that future studies should focus on understanding the biological reasons behind the increased susceptibility of certain racial minorities to BCRL, that surveillance, early detection, exercise programs, and arm compression can reduce the risk of BCRL...
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Giacomo Montagna Andrea V Barrio Source Type: research
Evidence-Based Strategies to Minimize the Likelihood of Axillary Lymph Node Dissection in Clinically Node-Positive Patients Following Neoadjuvant Chemotherapy
Surg Oncol Clin N Am. 2023 Oct;32(4):693-703. doi: 10.1016/j.soc.2023.05.003. Epub 2023 Jun 9.ABSTRACTDe-escalation of axillary management after neoadjuvant chemotherapy in clinically node-positive patients is feasible. The current literature shows this may be accomplished by sentinel lymph node biopsy (SLNB) with the use of dual tracer and removal of at least 2 sentinel lymph nodes, or by targeted axillary dissection (TAD). The accuracy of TAD has been consistently shown as better than that of SLNB. However, these techniques should only be offered to select patients without extensive axillary disease, understanding that l...
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Ashley A Woodfin Abigail S Caudle Source Type: research
Is Axillary Staging Obsolete in Early Breast Cancer?
This article reviews the incidence of nodal metastases in early-stage breast cancer and the need for axillary staging to maintain local control in the axilla or to determine the need for adjuvant systemic therapy across the spectrum of patients with breast cancer, and reviews clinical trials addressing this question. At present, sentinel lymph node biopsy should be omitted in women age ≥70 years with cT1-2 N0, HR+/HER2- cancers. The importance of nodal status in selecting patients for radiotherapy remains the main reason for axillary staging in younger postmenopausal women with cT1-2N0, HR+/HER2- cancers.PMID:37714636 | ...
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Monica Morrow Source Type: research
How to Navigate the Treatment Spectrum from Multimodality Therapy to Observation Alone for ductal carcinoma in situ
Surg Oncol Clin N Am. 2023 Oct;32(4):663-673. doi: 10.1016/j.soc.2023.05.011. Epub 2023 Jun 15.ABSTRACTDCIS detection has increased dramatically since the introduction of screening mammography. Current guidance concordant care recommends surgical intervention for all patients with DCIS, followed by radiation and/or endocrine therapy for some. Adjuvant therapies after surgical excision have reduced recurrence rates but not breast cancer mortality. Given the lack of evidence of current treatment regimens and the morbidity associated with these treatments, there is concern that DCIS is over-treated. Active surveillance may be...
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Sydney M Record Eun-Sil Shelley Hwang Akiko Chiba Source Type: research
